AzTrials
AzTrials

Diabetes (DM)FastForwardNCT07155993

FastForward: A Prospective Analysis of Long-term Fasting and Subsequent Food Reintroduction in Humans

An observational study of Diabetes (DM) and Pre Diabetes, run by Buchinger Wilhelmi Development & Holding GmbH at 1 site in Germany.

Enrolling by invitation

Enrolling by invitation. The study team selects and invites participants, usually from an existing group of patients.

Sites and contacts
Official record
Search all trials

Trial summary

This study explores what happens in the body and wellbeing during and after a period of long-term fasting. At the Buchinger Wilhelmi Clinic, participants follow a medically supervised fasting program lasting five or more days, followed by a structured food reintroduction phase. Read more about this study

Who is it for?
Ages 18 to 90 yearsHealthy volunteers can take part
How many people
300 participants
Where
1 siteGermany
Study dates
1 Aug 2024to Dec 2026
How long will I take part?
7 Months
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 90 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Study population: Patients of the Buchinger Wilhelmi clinic in Überlingen

Who may be able to join

  • Men and women
  • Fasting for 5+ days at the Buchinger Wilhelmi clinic in Überlingen or Marbella
  • Age: 18-90 years old
  • Signed informed consent

Who cannot join

  • Not able to sign the informed consent
  • Diagnosed with cachexia, anorexia nervosa, advanced kidney, liver or cerebrovascular insufficiency.
  • Chronic manifest psychical and psychiatric diseases
  • Participation in another study
  • Pregnancy or breastfeeding

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Germany1 site
  • Buchinger Wilhelmi Klinik

    Überlingen, Baden-Wurttemberg, 88662

Other trials in Germany

About this study

This study explores what happens in the body and wellbeing during and after a period of long-term fasting. At the Buchinger Wilhelmi Clinic, participants follow a medically supervised fasting program lasting five or more days, followed by a structured food reintroduction phase. The study observes participants over time to better understand how fasting and the return to eating affect weight, metabolism, nutrition habits, and overall well-being.

All participants will complete online questionnaires during the fasting phase and for up to three months afterward. These surveys help track changes in lifestyle, mood, and health. In addition during the first two weeks after fasting ends participants wear a continuous glucose monitor (CGM) to track blood sugar levels in real time, use a mobile app to document meals with photos, and perform simple at-home blood tests using dried blood spot (DBS) kits.

By combining digital tools with personal reports and at home tests, the study aims to gain a clearer picture of how the body adapts after a prolonged fast. The goal is to better understand the short- and medium-term effects of extended fasting on metabolism, diet, and well-being-and to provide practical guidance for those interested in fasting as a health practice.

Read the detailed description

Dear prospective study participants,

For optimal results of a fasting cure, the investigators would like to better understand the phase of food reintroduction, in which food is taken back after fasting.

The investigators would like to ask potential participants if they are willing to participate in the study of the Buchinger Wilhelmi Fasting Program. The study examines the post-fasting phase of food reintroduction. For this purpose, the first 14 days after the end of the fast are closely documented. This is done with the help of continuous glucose measurement and documentation of meals. In addition, various systemic biomarkers and the inflammatory status in blood are examined. In addition, further follow-up examinations take place after one and three months.

This study will include a total of more than 200 participants.

How will the study proceed and what investigations are planned?

The stay in the clinic begins with the admission examination by the study doctor, who explains the course of the study in detail and asks participants to sign the consent form. On the day of arrival, participants will receive an organic vegetarian dinner. This is followed by a "digestive rest day", a transitional day that is intended to prepare the body for the fasting phase. It consists of an easily digestible low-calorie mono-diet in three portions.

The fasting phase begins with a colon cleanse, e.g. with Glauber's salt. During fasting, the daily food intake consists of 1/4 l of freshly squeezed fruit or vegetable juice or 1/4 l of vegetable broth at noon, 1/4 l of vegetable broth in the evening and optionally 20 g of honey throughout the day. The end of fasting occurs individually after 7 or more (7+) days and is complemented by a phase of slow reintroduction of food with an ovo-lacto-vegetarian diet.

The study participants are offered the usual program of the Buchinger Wilhelmi Clinic. This includes fasting, physical exercise and individual treatments.

In addition to the admission examination, examinations take place during the clinic stay at the end of the fast and at the end of the food reintroduction.

The follow-up examinations 7, 14 and 21 days, one and three months after fasting take place independently from home. For study participants who live in the vicinity of the Buchinger Wilhelmi Clinic, the follow-up examinations take place after 14 days, one and three months on site at the Buchinger Wilhelmi Clinic in order to collect anthropometric data and take venous blood samples. If this applies to a participant, they will be contacted by the investigators.

If participants return to the clinic within 3 to 18 months after their initial stay, the investigators would carry out a follow-up examination including anthropometric measurements and a venous blood draw.

The following examinations will be carried out as part of the study:

Filling out questionnaires:

Participants will be asked about their lifestyle, their general health and their mental well-being before and at the end of the fast, at the end of the food reintroduction, 7, 14 and 21 days as well as one and three months after the fast. This will take about 15 minutes. During the fasting days and the first 14 days after fasting, participants will be asked daily about their well-being (approx. 5 minutes). All questionnaires are provided via the Buchinger Wilhelmi Amplius app and filled out in the app.

Documentation of anthropometric data:

During the stay, body weight, blood pressure and heart rate are measured daily in the morning by the nursing staff. The data is also recorded 7, 14 and 21 days, as well as one and three months after fasting through self-documentation. For this purpose, the body weight is measured at home on the scales. Blood pressure and heart rate are only measured at home if the appropriate devices are available. All values measured at home are entered into the Buchinger Wilhelmi Amplius app (there are fields in the questionnaires for this).

The waist circumference is measured at the beginning and end of fasting.

A bioelectrical impedance analysis (BIA) measurement takes place before fasting in the clinic. If participants come to the clinic for follow-up examinations, the measurement will take place again 14 days, one and three months after fasting. In BIA, body composition is measured by means of a weak current flow, which determines the percentage of muscle and fat mass in the body. The measurement must not be carried out in people with a pacemaker (tell the study doctor if this applies).

Blood analysis:

During the study, at least three, up to six, venous blood samples will be taken. On the first morning of the stay and at the end of the 7+ fasting days, as well as 3±2 days after breaking the fast, up to 30 ml of blood (amount of 2 tablespoons) is taken.

In addition, a total of 4 capillary blood samples are collected. On the first morning of the stay, as well as 14 days, one and three months after fasting. A small amount of blood is collected on blood collection swabs by a small prick in the fingertip. The capillary blood samples at the times after fasting must be taken by the participant themrselves with the equipment provided and sent by post to the research department of Buchinger Wilhelmi.

Blood sampling is a minimally invasive procedure in which a risk of side effects such as hematomas, infections, thrombosis or nerve damage cannot be ruled out.

Nutrition protocol:

From the day of breaking the fast, participants will log their meals for 14 days. To simplify this, the smartphone app "MyFoodRepo" is being used, developed by scientists for logging meals. This complies with the data protection guidelines of the GDPR. In the app, participants take a photo of all meals during the 14 days.

Continuous glucose measurement:

To measure the continuous glucose levels in blood, participants will wear a continuous glucose monitor for 14 days from the day of breaking the fast. To do this, a sensor with a fine filament similar to a needle is attached to the upper arm, which measures glucose during 24 hours. In study participants for whom the continuous measurement of the ketone bodies is also carried out, the continuous glucose measurement is already carried out from the digestive rest day (see next point).

There may be discomfort associated with wearing the sensor and there is a minimal risk of skin irritation or allergic reactions near the sensor site.

Documentation of ketone bodies in urine:

From the digestive rest day until 14 days after breaking the fast, participants will independently determine the ketone body content of the first morning urine with urine test strips every day and document the result in the Buchinger Wilhelmi Amplius app. The color change of the strip indicates the switch from energy production from glucose to energy production from fat reserves.

Collection of stool samples:

Three stool samples are collected, before the start of fasting, as soon as spontaneous bowel movements begin after fasting, and 14 days after fasting. The stool sample after 14 days must be taken independently with the equipment provided and sent by post to the research department of Buchinger Wilhelmi.

Keywords
long-term fasting, fasting, continuous glucose monitoring, food reintroduction, meal documentation
Medical subject headings
Diabetes Mellitus, Glucose Intolerance, Overweight, Fasting

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT07155993
Study groupRoleWhat they receive
Food reintroduction observation groupParticipants undergo a supervised long-term fast (≥5 days) followed by a structured food reintroduction at the Buchinger Wilhelmi Clinic. All participants complete online questionnaires assessing dietary habits, weight, and well-being during fasting and for up to 3 months afterward. Participants are monitored closely during the initial 14 days post-fasting with continuous glucose monitoring (CGM), photo-based meal tracking, and at-home dried blood spot sampling. Liquid venous blood and stool samples are collected at defined timepoints to analyze metabolic and physiological responses to fasting and food reintroduction.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Body weight

    Changes in body weight in the three-month period after a 5+ day fasting period according to the Buchinger Wilhelmi fasting program

    Measured: From the fasting start until 3 month after fasting

Secondary outcomes (11)
  1. Glycemic regulation

    Glycemic regulation will be assessed using glycated hemoglobin (HbA1c) measured in venous and/or capillary blood samples at baseline (D-1), 14 days, 1 month, and 3 months after fasting. In addition, continuous glucose monitoring (CGM) will be used during the 14 days following the fasting period.

    Measured: From the fasting start until 3 months after fasting

  2. Change in systemic inflammation

    To evaluate changes in systemic inflammation, blood samples will be analyzed for levels of C-reactive protein (CRP) at baseline, and again at 14 days, 1 month, and 3 months after the fasting intervention.

    Measured: From the fasting start until 3 months after fasting

  3. Change in systemic inflammation

    To evaluate changes in systemic inflammation, blood samples will be analyzed for white blood cell (WBC) counts at baseline, and again at 14 days, 1 month, and 3 months after the fasting intervention.

    Measured: From the fasting start until 3 months after fasting

  4. Eating behaviour

    Eating behaviour will be assessed with the MyFoodRepo smartphone app, used during the 14-day period following fasting, where participants photograph their meals. Macronutrient and micronutrient intake is extracted from the image-based food diary using an automated nutrient database.

    Measured: During the first 14 days after fasting

  5. Eating behaviour

    Eating behaviour will be assessed with a structured self-report questionnaire completed at baseline, 14 days, 1 month, and 3 months after fasting, assessing dietary patterns.

    Measured: From the fasting start until 3 months after fasting

  6. Resting energy expenditure

    Resting energy expenditure (REE) will be assessed in the morning, under fasted conditions, with participants lying down, using indirect calorimetry. Measurements will be taken at baseline and on the last day of the fasting period (which ranges from 5 to 25 days depending on individual fasting duration).

    Measured: From baseline (D-1) to the last day of fasting (Day 5 to Day 25)

  7. Wellbeing

    Subjective wellbeing will be assessed using the WHO-5 Well-Being Index, a validated 5-item questionnaire with a total score ranging from 0 (worst possible wellbeing) to 100 (best possible wellbeing). The questionnaire will be completed at baseline, 14 days, 1 month, and 3 months after fasting.

    Measured: From the fasting start until 3 months after fasting

  8. Wellbeing

    To assess subjective wellbeing during the fasting period and in the first 14 days post-fasting, participants will provide daily self-reported wellbeing ratings (non-validated), capturing fluctuations in mood, energy, and physical symptoms.

    Measured: From the fasting start until 14 days after fasting

  9. Lifestyle factors

    Lifestyle behaviour will be assessed using structured self-report questionnaires administered at baseline, 14 days, 1 month, and 3 months after fasting. Topics include:

    Physical activity (type, frequency, and duration) Sleep quality and duration Eating patterns, including eating windows and fasting behaviour Environmental health behaviours (e.g., time in nature, exposure to daylight) General nutrition and hydration practices

    Measured: From the fasting start until 3 months after fasting

  10. Ketone bodies

    Ketone body levels will be monitored during the fasting period and for 14 days after fasting. Measurements will be performed primarily via urine ketone test strips (acetoacetate), with some participants also performing capillary blood measurements of β-hydroxybutyrate using handheld meters.

    Measured: From the start of fasting until 2 weeks after fasting

  11. Adipose tissue composition

    Whole-body adipose tissue composition will be assessed using bioelectrical impedance analysis (BIA) at baseline, 14 days, 1 month, and 3 months after fasting. In a subset of participants, subcutaneous adipose tissue biopsies will be collected before fasting (baseline) and immediately after fasting (last day of fast; fasting duration varies between 5 and 25 days) to analyze tissue composition and cellular characteristics.

    Measured: BIA: baseline (Day -1), Day 14, 1 month, and 3 months after fasting Fat biopsies: before fasting (Day -1) and immediately after fasting (last day of fast)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted4 Sep 2025
  2. Study start1 Aug 2024
  3. Primary completionAug 2026 (estimated)
  4. Study completionDec 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
300 participants (estimated)
Target duration
7 Months
IDs, dates and publications
ClinicalTrials.gov ID
NCT07155993
Sponsor's protocol ID
F-2024-032
Acronym
FastForward
Status last verified
Sep 2025
First submitted
23 Jul 2025
Last updated
10 Sep 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Publications

  • Wilhelmi de Toledo F, Grundler F, Sirtori CR, Ruscica M. Unravelling the health effects of fasting: a long road from obesity treatment to healthy life span increase and improved cognition. Ann Med. 2020 Aug;52(5):147-161. doi: 10.1080/07853890.2020.1770849. Epub 2020 Jun 10.

    PubMed 32519900
  • Wilhelmi de Toledo F, Grundler F, Goutzourelas N, Tekos F, Vassi E, Mesnage R, Kouretas D. Influence of Long-Term Fasting on Blood Redox Status in Humans. Antioxidants (Basel). 2020 Jun 6;9(6):496. doi: 10.3390/antiox9060496.

    PubMed 32517172
  • Wilhelmi de Toledo F, Grundler F, Bergouignan A, Drinda S, Michalsen A. Safety, health improvement and well-being during a 4 to 21-day fasting period in an observational study including 1422 subjects. PLoS One. 2019 Jan 2;14(1):e0209353. doi: 10.1371/journal.pone.0209353. eCollection 2019.

    PubMed 30601864
  • Scharf E, Zeiler E, Ncube M, Kolbe P, Hwang SY, Goldhamer A, Myers TR. The Effects of Prolonged Water-Only Fasting and Refeeding on Markers of Cardiometabolic Risk. Nutrients. 2022 Mar 11;14(6):1183. doi: 10.3390/nu14061183.

    PubMed 35334843
  • Mesnage R, Grundler F, Schwiertz A, Le Maho Y, Wilhelmi de Toledo F. Changes in human gut microbiota composition are linked to the energy metabolic switch during 10 d of Buchinger fasting. J Nutr Sci. 2019 Nov 12;8:e36. doi: 10.1017/jns.2019.33. eCollection 2019.

    PubMed 31798864
  • Laurens C, Grundler F, Damiot A, Chery I, Le Maho AL, Zahariev A, Le Maho Y, Bergouignan A, Gauquelin-Koch G, Simon C, Blanc S, Wilhelmi de Toledo F. Is muscle and protein loss relevant in long-term fasting in healthy men? A prospective trial on physiological adaptations. J Cachexia Sarcopenia Muscle. 2021 Dec;12(6):1690-1703. doi: 10.1002/jcsm.12766. Epub 2021 Oct 20.

    PubMed 34668663
  • Muller H, de Toledo FW, Resch KL. Fasting followed by vegetarian diet in patients with rheumatoid arthritis: a systematic review. Scand J Rheumatol. 2001;30(1):1-10. doi: 10.1080/030097401750065256.

    PubMed 11252685
  • Grundler F, Plonne D, Mesnage R, Muller D, Sirtori CR, Ruscica M, Wilhelmi de Toledo F. Long-term fasting improves lipoprotein-associated atherogenic risk in humans. Eur J Nutr. 2021 Oct;60(7):4031-4044. doi: 10.1007/s00394-021-02578-0. Epub 2021 May 7.

    PubMed 33963431
  • Grundler F, Mesnage R, Michalsen A, Wilhelmi de Toledo F. Blood Pressure Changes in 1610 Subjects With and Without Antihypertensive Medication During Long-Term Fasting. J Am Heart Assoc. 2020 Dec;9(23):e018649. doi: 10.1161/JAHA.120.018649. Epub 2020 Nov 23.

    PubMed 33222606
  • Gabriel S, Ncube M, Zeiler E, Thompson N, Karlsen MC, Goldman DM, Glavas Z, Beauchesne A, Scharf E, Goldhamer AC, Myers TR. A Six-Week Follow-Up Study on the Sustained Effects of Prolonged Water-Only Fasting and Refeeding on Markers of Cardiometabolic Risk. Nutrients. 2022 Oct 15;14(20):4313. doi: 10.3390/nu14204313.

    PubMed 36296997
  • Drinda S, Grundler F, Neumann T, Lehmann T, Steckhan N, Michalsen A, Wilhelmi de Toledo F. Effects of Periodic Fasting on Fatty Liver Index-A Prospective Observational Study. Nutrients. 2019 Oct 30;11(11):2601. doi: 10.3390/nu11112601.

    PubMed 31671589
  • Buono R, Longo VD. When Fasting Gets Tough, the Tough Immune Cells Get Going-or Die. Cell. 2019 Aug 22;178(5):1038-1040. doi: 10.1016/j.cell.2019.07.052.

    PubMed 31442398
  • Beck RW, Calhoun P, Kollman C. Use of continuous glucose monitoring as an outcome measure in clinical trials. Diabetes Technol Ther. 2012 Oct;14(10):877-82. doi: 10.1089/dia.2012.0079.

    PubMed 23013201

Questions about this trial

What is this clinical trial studying?

An observational study of Diabetes (DM) and Pre Diabetes, run by Buchinger Wilhelmi Development & Holding GmbH at 1 site in Germany.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: enrolling by invitation, as of the sponsor's last update on 10 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Germany. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Body weight (time frame: From the fasting start until 3 month after fasting). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07155993, which also lists 13 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Sep 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in